Teva Pharmaceutical Industries Limited (NYSE:TEVA) declared a quarterly dividend on Thursday, November 2nd, RTT News reports. Stockholders of record on Tuesday, November 28th will be paid a dividend of 0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.46%.

Teva Pharmaceutical Industries Limited has increased its dividend by an average of 2.1% per year over the last three years. Teva Pharmaceutical Industries Limited has a payout ratio of 7.1% indicating that its dividend is sufficiently covered by earnings. Analysts expect Teva Pharmaceutical Industries Limited to earn $3.56 per share next year, which means the company should continue to be able to cover its $0.29 annual dividend with an expected future payout ratio of 8.1%.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.03). The company had revenue of $5.61 billion during the quarter, compared to analysts’ expectations of $5.61 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the company earned $1.31 earnings per share.

A number of equities research analysts have recently issued reports on the company. BidaskClub lowered Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 16th. Wells Fargo & Company lowered Teva Pharmaceutical Industries Limited to a “market perform” rating and dropped their price target for the company from $17.00 to $11.36 in a research report on Thursday. Citigroup Inc. lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and dropped their price target for the company from $32.00 to $19.00 in a research report on Wednesday, August 16th. Maxim Group restated a “hold” rating and issued a $35.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. Finally, Vetr lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating and set a $31.74 price target for the company. in a research report on Wednesday, July 12th. Five analysts have rated the stock with a sell rating, eighteen have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $27.51.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Plans $0.09 Quarterly Dividend” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/02/teva-pharmaceutical-industries-limited-teva-plans-0-09-quarterly-dividend.html.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Dividend History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.